<DOC>
	<DOCNO>NCT00426855</DOCNO>
	<brief_summary>The purpose study determine whether combination bendamustine bortezomib patient indolent Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia safe tolerable .</brief_summary>
	<brief_title>Bendamustine Bortezomib Combination Therapy Indolent Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description>Bendamustin bortezomib show effective treatment patient indolent Non-Hodgkin 's Lymphoma ( NHL ) Chronic Lymphocytic Leukemia ( CLL ) . Both compound appear cross-resistant prior therapy . Therefore , interest combine bendamustine bortezomib patient population . Preliminary result patient multiple myeloma show combination bendamustine bortezomib efficacious well tolerate . However , far data combination patient NHL CLL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Symptomatic recurrent refractory indolent NHL BCLL Adequate organ bone marrow function Karnofsky great 50 % Candidates autologous stem cell transplantation Secondary high grade lymphoma Concurrent severe medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Lymphoma , Non-Hodgkin , Low-Grade</keyword>
</DOC>